The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ApexOnco Front Page
Recent articles
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
The company will start its confirmatory bexobrutideg study in June.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
After setbacks, cema-cel might have a path to approval in lymphoma.
The group impresses in ovarian and endometrial cancers.
Optimum-02 virtually replicates phase 1, and a filing will follow.
